Biology Atlas

Map / Drugs

drug · intermediate · partly written

Trastuzumab (Herceptin)

Trastuzumab is an antibody against the HER2 receptor that, added to chemotherapy, lengthened survival in women whose breast cancer over-makes HER2, at the cost of heart damage.

Also called: Herceptin

This describes published medicine for readers who want to understand how it works and what happened. It is not medical advice and says nothing about what any person should take.

The short version

Trastuzumab is an antibody that sticks to HER2, a growth-signal receptor that 25 to 30 percent of breast cancers over-make. Added to chemotherapy in 469 women it lengthened median survival from 20.3 to 25.1 months. The cost was heart dysfunction, 27 percent versus 8 percent when given with an anthracycline. 1

Reported, not yet replicated

What it is and how it works more

A humanized IgG1 kappa antibody of about 148 kDa that binds the extracellular part of HER2. HER2 is a 185 kDa transmembrane receptor related to the EGF receptor. The label says trastuzumab inhibits proliferation of HER2-overexpressing tumour cells in laboratory assays and animals and mediates antibody-dependent cellular cytotoxicity (ADCC), in which immune cells recognise the antibody and kill the tagged cell. In vitro, that killing fell preferentially on cells over-making HER2. Because it works on a surface receptor, it reaches its target from the blood without entering cells. 2

Established

The decisive trial more

Slamon and colleagues randomised 469 women with metastatic breast cancer that over-made HER2 to chemotherapy alone (234) or chemotherapy plus trastuzumab (235). Adding trastuzumab lengthened median time to progression from 4.6 to 7.4 months and raised the response rate from 32 to 50 percent. One-year death fell from 33 to 22 percent, median survival rose from 20.3 to 25.1 months (P=0.01), and the risk of death was cut by 20 percent. Only the abstract was opened. 1

Reported, not yet replicated

The cost: the heart more

The most important adverse event was heart dysfunction of New York Heart Association class III or IV. With an anthracycline plus cyclophosphamide it occurred in 27 percent with trastuzumab versus 8 percent without; with paclitaxel, 13 percent versus 1 percent. The label carries a boxed warning for cardiomyopathy, with the highest incidence and severity in patients given an anthracycline-containing regimen, and requires left ventricular function to be evaluated before and during treatment. 12

Established

Target plus test deep

The drug is meant only for HER2-overexpressing disease, and the label says to select patients with an FDA-authorised companion diagnostic. This pairing of a target with a biomarker is why the same modality can be strikingly effective for a minority of cancers and irrelevant for the rest. 21

Established

Early disease deep

The label reports that in the pooled adjuvant studies NSABP B-31 and NCCTG N9831 the disease-free survival hazard ratio was 0.48 and overall survival hazard ratio 0.64; the HERA trial reported a disease-free survival hazard ratio of 0.54. These come from the label text, not from the trial papers, which were not opened. 2

Reported, not yet replicated

Modality

Therapeutic monoclonal antibodies

Targets

Pathways

Indications

Identifiers

Fda application number

761106 (Herceptin Hylecta, trastuzumab with hyaluronidase)

Mechanism

Binds the extracellular domain of HER2; inhibits proliferation of HER2-overexpressing tumour cells in assays and animals and mediates antibody-dependent cellular cytotoxicity. 2

Established

Delivery route

Must survive

It acts on a receptor on the cell surface, so it only has to travel in the blood and reach the tumour cell exterior; it does not have to enter cells. The label separates intravenous trastuzumab from the subcutaneous product, which must not be given intravenously, and the subcutaneous product adds hyaluronidase to help dispersion and absorption. The intravenous form is named in the label as a separate product. 2

Established

Side effects

Cardiomyopathy and heart dysfunction

NYHA class III or IV dysfunction in 27 percent with anthracycline, cyclophosphamide and trastuzumab versus 8 percent without; 13 percent with paclitaxel and trastuzumab versus 1 percent without. Boxed warning in the label. 12

Reported, not yet replicated

Heart findings with the subcutaneous product

In the SafeHER study, 17 percent (323 of 1864) reported a cardiac disorder; decreased ejection fraction 4.5 percent (84 of 1864) and congestive cardiac failure under 1 percent. 2

Reported, not yet replicated

Pulmonary toxicity and embryo-fetal toxicity

Both are named in the boxed warning; frequencies were not read. 2

Reported, not yet replicated

Common reactions

Fatigue, arthralgia, diarrhoea, injection site reaction, upper respiratory infection, rash, myalgia, nausea, headache, oedema, flushing, pyrexia, cough and pain in extremity were the most common (10 percent or more) in adjuvant use of the subcutaneous product. 2

Reported, not yet replicated

Verdict

Outcome

worked

Why

Randomised evidence in HER2-positive disease showed longer progression-free time and survival (Slamon 2001); the benefit comes with a known, monitored heart risk. Selecting patients by a companion test is what let a single-target antibody work. 12

Reported, not yet replicated

Teach this

In one sentence

Trastuzumab is an antibody that binds the HER2 receptor on tumour cells and, with chemotherapy, extended survival in HER2-positive breast cancer while adding a heart-damage risk. 12

Reported, not yet replicated

The five-minute version

HER2 is a growth-signal receptor sitting on the cell surface, and some breast cancers make far too much of it. Trastuzumab is a large antibody that sticks to the outer part of HER2, slows the cells and flags them for killing by immune cells. The pivotal trial gave chemotherapy with or without it to 469 women and found median survival of 25.1 versus 20.3 months, but heart dysfunction was far more common when combined with an anthracycline. A companion test decides who is eligible. 12

Reported, not yet replicated

What a listener will ask

Does it work for all breast cancer?

No. The label limits it to HER2-overexpressing disease chosen with a companion diagnostic, and the trial enrolled only such patients (Slamon 2001). 12

Reported, not yet replicated

Why is the heart affected?

The sources opened say that it happens and how often, and that it is worst with an anthracycline; they do not state a mechanism.

How do the animals compare?

The label describes animal and cell-line results for tumour proliferation; the contrast with TGN1412 is that its target biology was not matched in the animals. 12

Reported, not yet replicated

The common wrong idea

An antibody drug is just a very selective drug, so its side effects would be mild and mostly off-target.

The worst harm here is on-label and combination-dependent: 27 percent versus 8 percent heart dysfunction with an anthracycline, and a boxed warning (Slamon 2001; FDA label). 12

Reported, not yet replicated

The one citation to hand over: 1

Still open here

Not yet written: Year, Assays used, Off targets.

Linked from

Sources

  1. Slamon DJ, et al.. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792 (2001). paper; opened 2026-11-17 all records citing this
  2. Genentech, Inc.. Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) prescribing information. FDA Drugs@FDA label, application 761106 (2026). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
History of this record (5)

This record has been changed 5 times, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.

Regulatory status
approved
Status
partly written
Last updated
2026-11-19
Record
content/drugs/trastuzumab.json